Wednesday, October 8


Wednesday, October 8

(The presenters of gray titles did not allow the online appearance of their lectures )


40. MOLECULAR AND CELLULAR BIOLOGY OF CANCER

ROOM A, 08.00-16.45 – Wednesday, October 8

Chair Persons: B. Kaina, M.M. Müller

Chair Persons: T. Isbir, Q. Wang

Chair Persons: F.L. Queiroga, J. Schneider


41. CYTOGENETICS AND GENETICS

ROOM A, 17.00-19.30 – Wednesday, October 8

Chair Persons: W. Weber, I. Kiss

  • Familial cancer: The alert clinician and UICC. W. Weber (Basel, Switzerland) (15’)
  • Role of allelic polymorphisms in the susceptibility to colorectal and head- and neck cancers. I. Kiss, Z.S. Orsós, J. Cseh, A.Csejtei, I. Szanyi, G. Pajkos, A. Németh (Pecs; Székesfehérvár; Szombathely; Kecskemét, Hungary) (20’)
  • Association between ERCC2 gene polymorphism and primary ovarian cancer. G. Yildirim, R. Attar, C. Fiçicioglu, Gulec-Yilmaz, Ö Timirci-Kahraman, H. Atasoy , Ö Kizilkale-Yildirim, C. Iyibozkurt, A. Buyukoren, A.B. Dalan, B. Çakmakoglu, A. Ergen, T. Isbir (Istanbul, Turkey) (20’)
  • Etiological observations in 7 patients with pancreatic neuroendocrine tumors (PNETs). W. Weber (Basel, Switzerland) (15’)
  • RRM1 and RRM2 gene polymorphisms in patients with primary ovarian cancer. R. Attar, G. Yildirim, C. Fiçicioglu, S. Gulec-Yilmaz, Ö Timirci-Kahraman, H. Atasoy, Ö Kizilkale-Yildirim, C. Iyibozkurt, A. Buyukoren, A.B. Dalan, I. Yaylim, U. Görmüs,T. Isbir (Istanbul, Turkey) (20’)
  • Silent mutation in HLA-E gene is associated with Tunisian nasopharyngeal cancer. H. Douik, N.A. Romdhane, C. Fortier, M. Makni, L. Harzallah, R. Khrishnammorthy, D. Charron, R. Tamouza, F. Guemira (Tunis, Tunisie; Paris, France) (15’)
  • Relationship of genetic polymorphism of transforming growth factor-beta1 (TGF-ß1) with urinary bladder cancer – a cases-control study on North Indian population. Kirti, S.N. Sankhwar, R. Singh, P.L. Sankhwar, A. Goel, D. Dalela (Lucknow, Uttar Pradesh, India) (10’)

42. MULTI-DRUG AND DRUG RESISTANCE: MECHANISMS AND REVERSAL

ROOM B, 8.00-12.00 – Wednesday, October 8

Chair Persons: L. Amaral, J. Molnar

  • Similar responses of MDR cancer and bacteria to the same inhibitor of efflux pumps in general. L. Amaral, J. Molnar (Lisbon, Portugal; Szeged, Hungary) (20’)
  • Heat-shock protein HSP27 in anticancer mechanisms. M.B. Stope, U. Zimmermann, R. Walther, M. Burchardt (Griefswald, Germany) (25’)
  • Plant-derived compounds for modulating pgp-mediated mdr in cancer cells. M.-J.U. Ferreira (Lisbon,Portugal) (30’)
  • Antitumour effects of selected plant polyphenols, gallic acid and ellagic acid, on sensitive and multidrug resistant leukaemia HL60 cells. A. Maruszewska, J. Tarasiuk (Szczecin, Poland) (30’)
  • P-glycoprotein expression is downregulated by temozolomide in glioblastoma stem cells. I.C. Salaroglio, V. Caldera, I. Campia, J. Kopecka, M. Mellai, L. Annovazzi, A. Bosia, D. Ghigo, D. Schiffer, C. Riganti (Turin; Vercelli, Italy) (10’)
  • Edysteroids potentiate the activity of doxorubicin in cancer. A. Martins, J. Csabi, J. Molnár, L. Amaral, A. Hunyadi (Szeged, Hungary; Lisbon, Portugal) (15’)
  • Multidrug resistance reversing activity of newly developed phenothiazines on p glycoprotein (ABCB1)-related resistance in different cancer models. G. Spengler, D. Takács, Z. Riedl, G. Hajós, L. Amaral, J. Molnár (Szeged; Budapest, Hungary; Lisbon, Portugal) (15’)
  • Semi- and total-synthetic protoflavone derivatives as MDR selective anticancer agents. B. Dankó, A. Martins, L. Amaral, J. Molnár, M. Pešic, G. Szakács, A. Hunyadi (Szeged; Budapest, Hungary; Lisbon, Portugal; Belgrade, Serbia) (15’)
  • SILAC-based analysis reveals a unique phosphoproteomic-signature of HER2-resistant breast cancer cells. J.F.G. Nunes, H. Zhang, J. Stebbing, N. Angelopoulos, G. Giamas (London, UK) (15’)
  • Effects of ABCE1 downregulation by RNAi on chemosensitivity of lung cancer cells. G. Kara, S. Tuncer, M. Turk, E.M. Denkbas (Beytepe, Ankara; Yahsihan, Kirikkale, Turkey) (15’)

43. DIAGNOSIS AND PROGNOSIS OF CANCER

ROOM B, 13.00-16.00 – Wednesday, October 8

Chair Persons: P. Ferroni, C. Sansom, G. Karanikas

  • Fluorodeoxyglucose uptake in advanced non-small cell lung cancer with and without pulmonary lymphangitic carcinomatosis. H. Ooi, C.Y. Chen, Y.C. Hsiao, W.S. Huang, B.T. Hsieh (Taichung, Taiwan) (40’)
  • Expression of antigen processing machinery components in tonsillar (TSCC) and Base Of Tongue Cancer (BOTSCC) in relation to Human Papillomavirus (HPV) and clinical outcome. T. Ramqvist, N. Tertipis, L. Haeggblom, C. Nordfors, N. Grün, A. Näsman, A. Vlastos, T. Dalianis (Stockholm, Sweden) (15’)
  • Clinical value of scintimammography in diagnosis, treatment monitoring and follow- up. M.R. El-Zahry, M. Rodrigues-Radischat, P. Berghammer, H. Sinzinger (Vienna, Austria) (25’) – In process
  • New predictors of venous thromboembolism in ambulatory cancer patients. P. Ferroni (Rome, Italy) (30’)
  • Evaluation of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) in detection of suspected extra adrenal paraganglioma. G. Karanikas, K. El-Rabadi, A. Khameneh, M. Weber, M. Mayerhoefer, M. Hacker (Vienna, Austria) (10’)
  • MicroRNAs in cerebrospinal fluid – potential diagnostic tools for CNS lymphomas. M. Chechlinska, M. Zajdel, G. Rymkiewicz, M. Cieslikowska, K. Blachnio, Z. Bystydzienski , K. Goryca, A. Druzd-Sitek, M. Sromek, J. Walewski, J.K. Siwicki (Warsaw, Poland) (10’)
  • Correlation of RCAS1 and CD3 expression and their clinical significance in non-small cell lung cancers. N. Tsoukalas, C. Giaginis, S. Siakavellas, I. Kostakis, M. Tolia, M. Kiakou, E. Bournakis, A. Papakostidi, I. Sfiniadakis, A. Karameris, S. Theocharis (Athens, Greece) (10’)

44. NUTRITION AND CANCER. NUTRITIONAL ASPECTS OF CANCER PREVENTION

ROOM B, 16.15-18.45 – Wednesday, October 8

Chair Person : G. Vollmer, S.A. Lamprecht, N. Abu Freha


45. NEW ANTICANCER AGENTS

ROOM C, 08.00-15.00 – Wednesday, October 8

Chair Persons: S. Sarkar, P. Collery

Chair Persons: J. Anastassopoulou, S. Kottaridis


47. CANCER SURGERY

ROOM C, 15.15-19.30 – Wednesday, October 8

Chair Persons: T. Yoshizumi, N. Tsoukalas

Chair Persons: T. Okamoto, H. Saeki


48. BRAIN CANCER TREATMENT: EPIGENETIC NETWORKS
Special Symposium Organized by E. Benericetti and R. Nano

ROOM D, 8.00-15.00 – Wednesday, October 8

Chair Persons: E. Benericetti, R. Nano, D. Schiffer


49. CLINICAL CHEMOTHERAPY

ROOM D, 15.15-19.30 – Wednesday, October 8

Chair Persons: T. Aoki, J. Slansky, M. I. Panagiotidis


50. PKC SIGNALING IN CANCER
Special Symposium Organized by A.P. Fields

ROOM E, 08.00-12.00 – Wednesday, October 8

Chair Person: A.P. Fields


51. HEPATOCELLULAR CARCINOMA
Special Symposium Organized by K. Kubota

ROOM E, 13.00-15.00 – Wednesday, October 8

Chair Person: K. Kubota


52. INVASION AND CARCINOMAS OF THE GI TRACT
Special Symposium Organized by O.D. Laerum

ROOM E, 15.10-17.10 – Wednesday, October 8

Chair Person: O.D. Laerum


53. DRUG RESISTANCE IN CANCER AND TARGETING DNA REPAIR PATHWAYS
Special Symposium Organized by S. Mitra and B. Kaina

ROOM E, 17.20-19.30 – Wednesday, October 8

Chair Persons: S. Mitra, B. Kaina


54. BIOBANKS: A RESEARCH INFRASTRUCTURE FOR THE FUTURE OF TRANSLATIONAL AND CLINICAL RESEARCH
Special Symposium of the International Society for Biological and Environmental Repositories (ISBER), Organized by F. Betsou and F. Guadagni

ROOM F, 8.00-14.00 – Wednesday, October 8

Chair Persons: F. Guadagni, E. Briasoulis
Introduction : F. Guadagni

Chair Persons: F. Betsou, M. Roselli

Conclusion : F. Betsou


55. HYPOXIA AND CANCER CELL PROTECTION IN CANCER METASTASIS
Special Symposium Organized by G. Rutterman

ROOM F, 14.15-18.30 – Wednesday, October 8

Chair Persons: G. Rutteman, J.T. de Oliveira